About Bijoy Hans Limited
Bijoy Hans Limited is a publicly listed company based in Guwahati (India). It operates as a pharmaceutical formulations manufacturing and related services in Guwahati, India. Its Indian entity Arvaya Healthcare Limited reported revenue of ₹46.9 Lakh. Bijoy Hans Limited offers products and services including Pharmaceutical Formulations and Nutraceuticals. Its focus areas include Nutraceuticals, Health Supplements, Nutritional Products and Pharmaceuticals.
Company details
Bijoy Hans Limited was incorporated in 1985 and is situated in Guwahati, where various pharmaceutical formulations such as tablets, capsules, syrups, suspensions, and powders are produced. A focus is placed on segments including Antibiotics, CoughColdAllergy remedies, H-1 Receptor Antagonists, Nutraceuticals, and NSAIDS. The companys objectives are centered on benefiting shareholders, meeting customer requirements, ensuring continuous product improvement, and delivering sustainable excellence in health, safety, security, and environmental practices. Compliance with regulations is maintained through regular financial reporting and investor relations activities.
- Headquarters Guwahati, India
- Stage Public
- SectorsHealthcare
- Email••••••••
- Legal Name Bijoy Hans Ltd.
- Market Cap₹465 Cr
ARVAYA · BSE
- Share Price₹98.80
+1.96% today
- Revenue₹9.11 Cr
FY 2025-26 · +3153.6% YoY
- EBITDA₹0.73 Cr
Margin 8.0%
- Net Profit₹0.89 Cr
FY 2025-26 · +285.4% YoY
- ROE2.7%
ROCE 2.6%
- Debt / Equity0.74
Interest cover 390.9x
Associated legal entities of Bijoy Hans Limited
Bijoy Hans Limited is associated with 2 registered companies on The Company Check; the primary company is Arvaya Healthcare Limited, a listed company. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Arvaya Healthcare Limited Listed CIN L86100AS1985PLC002323 | Active | 26 Mar 1985 | Gmc, Assam | ₹0.5 Cr | – | 9 | View details |
| Bijoy Hans Limited CIN L51909AS1985PLC002323 | – | 26 Mar 1985 | Guwahati, Assam, India | – | – | – | View details |
Products & Services of Bijoy Hans Limited
Bijoy Hans Limited offers a comprehensive portfolio of products and services, including Pharmaceutical Formulations and Nutraceuticals.
Various formulations including tablets and capsules are manufactured for medical use
Nutritional products are provided in segments like powders and syrups for health support
Board of directors of Arvaya Healthcare Limited (Bijoy Hans Limited)
Arvaya Healthcare Limited is the primary company behind Bijoy Hans Limited. The board of Arvaya Healthcare Limited currently have 6 directors; the longest-serving is Salil Sriram Shetty, appointed in 2024. 18 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Salil Sriram Shetty DIN 07424136 | Director | 13 Aug 2024 | 2 yrs 2 mo | Arvaya Healthcare Limited |
| Kaushal Uttam Shah DIN 02175130 | Managing Director | 26 May 2025 | 1 yr 4 mo | Arvaya Healthcare Limited |
| Rahul Ravindra Mayur DIN 09203474 | Director | 28 Jul 2025 | 1 yr 2 mo | Arvaya Healthcare Limited |
| Brijesh Jugalkishor Biyani DIN 10763751 | Director | 28 Jul 2025 | 1 yr 2 mo | Arvaya Healthcare Limited |
| Manali Aditya Pandit DIN 11495478 | Director | 31 Jan 2026 | 8 mo | Arvaya Healthcare Limited |
| Bidari Kotresh Anilkumar DIN 06624790 | Additional Director | 04 Jul 2026 | 3 mo | Arvaya Healthcare Limited |
IPO & Listings of Bijoy Hans Limited
Bijoy Hans Limited is a publicly listed company on the BSE with ticker symbol ARVAYA in India, operating in the Distribution services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date18 Jul 2005
- Listed onBSE: ARVAYA
- Listed entityArvaya Healthcare Ltd
- Exchange sectorDistribution services
- ISININE491D01017
- Share price₹57.99 (+5% on the day) · 2026-05-11
- Volume (last session)178
- Analyst consensusNo rating
Financials of Bijoy Hans Limited
Exchange-reported figures of Arvaya Healthcare Limited, the listed company behind Bijoy Hans Limited (BSE: ARVAYA).
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Income statement | ||
| Revenue | 9.11 | 0.28 |
| Revenue growth | +3153.6% | - |
| EBITDA | 0.73 | (0.53) |
| EBITDA margin | +8.0% | -189.3% |
| Profit before tax | 1.08 | 0.19 |
| Net profit | 0.89 | (0.48) |
| Net profit margin | +9.8% | -171.4% |
| EPS (₹) | 0.19 | 0.45 |
| Balance sheet | ||
| Total assets | 114 | 3.53 |
| Net worth | 63.07 | 3.53 |
| Total debt | 49.38 | 0.00 |
| Cash & bank | 2.35 | 2.71 |
| Net working capital | 11.32 | 2.93 |
| Cash flow | ||
| Cash from operations | (3.28) | 0.22 |
| Cash from investing | (5.58) | 0.92 |
| Cash from financing | 8.50 | (0.06) |
| Particulars | Jun 2026 | Mar 2026 | Jun 2025 |
|---|---|---|---|
| Revenue | 29.91 | 9.11 | 0.00 |
| Other income | 0.19 | 1.30 | 0.03 |
| EBITDA | 3.97 | 1.39 | (0.29) |
| EBITDA margin | +13.3% | +15.3% | - |
| Depreciation | 2.20 | 0.62 | 0.00 |
| Interest | 1.39 | 0.41 | 0.00 |
| Profit before tax | 0.57 | 1.66 | (0.26) |
| Tax | 0.03 | 0.19 | 0.00 |
| Net profit | 0.54 | 1.47 | (0.26) |
| EPS (₹) | 0.08 | 1.25 | (0.53) |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 0.00 | 0.28 | 0.28 | 0.30 | 0.33 | 0.40 | 0.49 |
| Revenue growth | -100.0% | 0.0% | -6.7% | -9.1% | -17.5% | -18.4% | - |
| EBITDA | (1.37) | 0.03 | (0.36) | (0.51) | (0.30) | (0.27) | (0.23) |
| EBITDA margin | - | +10.7% | -128.6% | -170.0% | -90.9% | -67.5% | -46.9% |
| Profit before tax | (1.20) | 0.19 | (0.12) | (0.44) | (0.18) | (0.10) | (0.04) |
| Net profit | (1.20) | (0.43) | (0.26) | (0.44) | (0.18) | (0.10) | (0.04) |
| Net profit margin | - | -153.6% | -92.9% | -146.7% | -54.6% | -25.0% | -8.2% |
| EPS (₹) | (1.18) | 0.45 | (0.39) | (1.48) | (0.63) | (0.30) | (0.18) |
| Balance sheet | |||||||
| Total assets | 60.51 | 3.53 | 3.45 | 3.59 | 3.95 | 4.14 | 4.23 |
| Net worth | 57.99 | 3.53 | 3.39 | 3.51 | 3.95 | 4.14 | 4.23 |
| Total debt | 2.52 | 0.00 | 0.06 | 0.08 | 0.00 | 0.00 | 0.00 |
| Cash & bank | 0.02 | 2.71 | 1.63 | 1.62 | 1.91 | 2.28 | 2.29 |
| Net working capital | (0.26) | 2.93 | 1.82 | 1.80 | 2.76 | 2.76 | 2.98 |
| Cash flow | |||||||
| Cash from operations | (7.89) | 0.22 | (0.29) | (0.26) | (0.37) | (0.01) | (0.07) |
| Cash from investing | (2.33) | 0.92 | 0.32 | (0.11) | 0.00 | 0.00 | (0.01) |
| Cash from financing | 7.53 | (0.06) | (0.02) | 0.08 | 0.00 | 0.00 | (0.02) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.13 | 0.06 |
| Revenue growth (YoY) | - | - | -100.0% | -100.0% | -100.0% | - | - | - |
| Other income | 0.06 | 0.07 | 0.05 | 0.02 | 0.03 | 0.05 | 0.61 | 0.04 |
| Total expenses | 0.90 | 0.70 | 0.21 | 0.33 | 0.29 | 0.19 | 0.20 | 0.23 |
| EBITDA | (0.80) | (0.70) | (0.21) | (0.33) | (0.29) | (0.19) | (0.07) | (0.17) |
| EBITDA margin | -800.0% | - | - | - | - | - | -53.8% | -283.3% |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| Interest | 0.14 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
| Profit before tax | (0.88) | (0.63) | (0.16) | (0.31) | (0.26) | (0.15) | 0.53 | (0.14) |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 | 0.00 | 0.00 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Jun 2025 |
|---|---|---|---|
| Revenue | 29.91 | 9.11 | 0.00 |
| Other income | 0.19 | 1.30 | 0.03 |
| EBITDA | 3.97 | 1.39 | (0.29) |
| EBITDA margin | +13.3% | +15.3% | - |
| Depreciation | 2.20 | 0.62 | 0.00 |
| Interest | 1.39 | 0.41 | 0.00 |
| Profit before tax | 0.57 | 1.66 | (0.26) |
| Tax | 0.03 | 0.19 | 0.00 |
| Net profit | 0.54 | 1.47 | (0.26) |
| EPS (₹) | 0.08 | 1.25 | (0.53) |
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Revenue | 9.11 | 0.28 |
| Revenue growth | +3153.6% | - |
| Other income | 1.40 | 0.75 |
| Total expenses | 8.38 | 0.81 |
| Employee cost | 1.90 | 0.16 |
| EBITDA | 0.73 | (0.53) |
| EBITDA margin | +8.0% | -189.3% |
| Depreciation | 0.62 | 0.02 |
| Interest | 0.43 | 0.01 |
| Profit before tax | 1.08 | 0.19 |
| Tax | 0.19 | 0.06 |
| Net profit | 0.89 | (0.48) |
| Net profit margin | +9.8% | -171.4% |
| EPS (₹) | 0.19 | 0.45 |
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Equity & liabilities | ||
| Share capital | 48.02 | 3.00 |
| Reserves & surplus | 11.88 | 0.53 |
| Shareholders' funds (net worth) | 63.07 | 3.53 |
| Minority interest | 0.00 | 0.00 |
| Secured loans | 8.60 | 0.00 |
| Unsecured loans | 40.78 | 0.00 |
| Total debt | 49.38 | 0.00 |
| Total liabilities | 114 | 3.53 |
| Assets | ||
| Gross block | 105 | 0.00 |
| Net block | 92.04 | 0.00 |
| Capital work in progress | 0.00 | 0.00 |
| Investments | 0.16 | 0.13 |
| Inventories | 1.90 | 0.00 |
| Sundry debtors | 2.20 | 0.00 |
| Cash & bank balances | 2.35 | 2.71 |
| Loans & advances | 31.64 | 0.28 |
| Total current assets | 38.09 | 2.99 |
| Total current liabilities | 26.77 | 0.06 |
| Net working capital | 11.32 | 2.93 |
| Total assets | 114 | 3.53 |
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Opening cash | 2.71 | 1.63 |
| Net cash from operating activities | (3.28) | 0.22 |
| Net cash from investing activities | (5.58) | 0.92 |
| Net cash from financing activities | 8.50 | (0.06) |
| Net change in cash | (0.36) | 1.08 |
| Closing cash | 2.35 | 2.71 |
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Growth | ||
| Sales growth | +3153.6% | - |
| EBITDA growth | +237.7% | - |
| PBT growth | +468.4% | +9997.0% |
| Net income growth | +285.4% | - |
| Profitability & leverage | ||
| Net income margin | +9.8% | +46.4% |
| Return on capital employed | +2.6% | -10.9% |
| Return on net worth | +2.7% | -13.3% |
| Debt / equity | 0.74 | 0.00 |
| Long-term debt / equity | 0.65 | 0.00 |
| Interest cover | 390.91 | -1.82 |
| Efficiency & per share | ||
| Fixed asset turnover | 0.17 | 0.00 |
| Inventory turnover | 9.59 | 0.00 |
| Debtors turnover | 8.28 | 0.00 |
| EPS (₹) | 0.19 | 0.45 |
| Dividend per share (₹) | 0.00 | 0.00 |
| Book value per share (₹) | 12.47 | 11.76 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.13 | 0.06 |
| Revenue growth (YoY) | - | - | -100.0% | -100.0% | -100.0% | - | - | - |
| Other income | 0.06 | 0.07 | 0.05 | 0.02 | 0.03 | 0.05 | 0.61 | 0.04 |
| Total expenses | 0.90 | 0.70 | 0.21 | 0.33 | 0.29 | 0.19 | 0.20 | 0.23 |
| EBITDA | (0.80) | (0.70) | (0.21) | (0.33) | (0.29) | (0.19) | (0.07) | (0.17) |
| EBITDA margin | -800.0% | - | - | - | - | - | -53.8% | -283.3% |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| Interest | 0.14 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
| Profit before tax | (0.88) | (0.63) | (0.16) | (0.31) | (0.26) | (0.15) | 0.53 | (0.14) |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 | 0.00 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.28 | 0.28 | 0.30 | 0.33 | 0.40 | 0.49 |
| Revenue growth | -100.0% | 0.0% | -6.7% | -9.1% | -17.5% | -18.4% | - |
| Other income | 0.17 | 0.19 | 0.30 | 0.14 | 0.15 | 0.21 | 0.24 |
| Total expenses | 1.37 | 0.25 | 0.64 | 0.81 | 0.63 | 0.67 | 0.72 |
| Employee cost | 0.00 | 0.16 | 0.16 | 0.18 | 0.17 | 0.17 | 0.17 |
| EBITDA | (1.37) | 0.03 | (0.36) | (0.51) | (0.30) | (0.27) | (0.23) |
| EBITDA margin | - | +10.7% | -128.6% | -170.0% | -90.9% | -67.5% | -46.9% |
| Depreciation | 0.00 | 0.02 | 0.05 | 0.06 | 0.03 | 0.04 | 0.05 |
| Interest | 0.00 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (1.20) | 0.19 | (0.12) | (0.44) | (0.18) | (0.10) | (0.04) |
| Tax | 0.00 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net profit | (1.20) | (0.43) | (0.26) | (0.44) | (0.18) | (0.10) | (0.04) |
| Net profit margin | - | -153.6% | -92.9% | -146.7% | -54.6% | -25.0% | -8.2% |
| EPS (₹) | (1.18) | 0.45 | (0.39) | (1.48) | (0.63) | (0.30) | (0.18) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 48.02 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
| Reserves & surplus | 9.97 | 0.53 | 0.39 | 0.51 | 0.95 | 1.14 | 1.23 |
| Shareholders' funds (net worth) | 57.99 | 3.53 | 3.39 | 3.51 | 3.95 | 4.14 | 4.23 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 2.52 | 0.00 | 0.06 | 0.08 | 0.00 | 0.00 | 0.00 |
| Total debt | 2.52 | 0.00 | 0.06 | 0.08 | 0.00 | 0.00 | 0.00 |
| Total liabilities | 60.51 | 3.53 | 3.45 | 3.59 | 3.95 | 4.14 | 4.23 |
| Assets | |||||||
| Gross block | 0.00 | 0.00 | 1.37 | 1.68 | 1.64 | 1.64 | 1.63 |
| Net block | 0.00 | 0.00 | 0.40 | 0.76 | 0.71 | 0.74 | 0.77 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 60.78 | 0.13 | 0.38 | 0.20 | 0.14 | 0.05 | 0.05 |
| Inventories | 0.00 | 0.00 | 0.05 | 0.04 | 0.07 | 0.10 | 0.05 |
| Sundry debtors | 0.00 | 0.00 | 0.08 | 0.09 | 0.08 | 0.13 | 0.17 |
| Cash & bank balances | 0.02 | 2.71 | 1.63 | 1.62 | 1.91 | 2.28 | 2.29 |
| Loans & advances | 7.57 | 0.28 | 0.10 | 0.09 | 0.74 | 0.28 | 0.51 |
| Total current assets | 7.59 | 2.99 | 1.86 | 1.84 | 2.80 | 2.79 | 3.02 |
| Total current liabilities | 7.85 | 0.06 | 0.04 | 0.04 | 0.04 | 0.03 | 0.04 |
| Net working capital | (0.26) | 2.93 | 1.82 | 1.80 | 2.76 | 2.76 | 2.98 |
| Total assets | 60.51 | 3.53 | 3.45 | 3.59 | 3.95 | 4.14 | 4.23 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 2.71 | 1.63 | 1.62 | 1.91 | 2.28 | 2.29 | 2.40 |
| Net cash from operating activities | (7.89) | 0.22 | (0.29) | (0.26) | (0.37) | (0.01) | (0.07) |
| Net cash from investing activities | (2.33) | 0.92 | 0.32 | (0.11) | 0.00 | 0.00 | (0.01) |
| Net cash from financing activities | 7.53 | (0.06) | (0.02) | 0.08 | 0.00 | 0.00 | (0.02) |
| Net change in cash | (2.69) | 1.08 | 0.01 | (0.29) | (0.37) | (0.02) | (0.10) |
| Closing cash | 0.02 | 2.71 | 1.63 | 1.62 | 1.91 | 2.28 | 2.29 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -100.0% | 0.0% | -6.7% | -9.1% | -17.5% | -18.4% | - |
| EBITDA growth | -4666.7% | +108.3% | +29.4% | -70.0% | -11.1% | -17.4% | - |
| PBT growth | - | +9998.0% | +72.7% | -144.4% | -80.0% | -150.0% | +42.9% |
| Net income growth | -179.1% | -65.4% | +40.9% | -144.4% | -80.0% | -150.0% | - |
| Revenue CAGR (3Y) | -100.0% | -5.3% | -11.2% | -15.1% | -6.2% | -3.1% | -28.3% |
| EBITDA CAGR (3Y) | +39.0% | - | +10.1% | +30.4% | +7.7% | 0.0% | -5.2% |
| Profitability & leverage | |||||||
| Net income margin | - | +46.4% | -42.9% | -146.7% | -54.6% | -25.0% | -8.2% |
| Return on capital employed | - | -10.9% | -7.1% | -11.4% | -4.7% | -2.2% | -1.2% |
| Return on net worth | - | -12.1% | -7.5% | -11.8% | -4.7% | -2.2% | -1.2% |
| Debt / equity | - | 0.01 | 0.02 | 0.01 | 0.00 | 0.00 | 0.00 |
| Long-term debt / equity | - | 0.01 | 0.02 | 0.01 | 0.00 | 0.00 | 0.00 |
| Interest cover | 0.00 | 100.00 | -2.44 | -1.75 | 0.00 | 0.00 | 0.00 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 0.41 | 0.18 | 0.18 | 0.20 | 0.24 | 0.30 |
| Inventory turnover | - | 11.20 | 6.22 | 5.45 | 3.88 | 5.33 | 8.17 |
| Debtors turnover | - | 7.00 | 3.29 | 3.53 | 3.14 | 2.67 | 3.63 |
| EPS (₹) | (1.18) | 0.45 | (0.39) | (1.48) | (0.63) | (0.30) | (0.18) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 11.76 | 11.31 | 11.70 | 13.18 | 13.80 | 14.10 |
Top companies in Alternative Medicine Products
10 companies that operate in the same segment as Bijoy Hans Limited (Alternative Medicine Products), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Homeopathic medicine manufacturing and online retail in India. | 1898 | Noida, Uttar Pradesh, India | – | USD 26.35 M | 1,192 | |
Operates an online store specializing in ayurvedic and homeopathic medicines. | 2016 | Delhi, Delhi, India | – | USD 1.25 M | 16 | |
Pharmaceutical therapies for smell and taste loss are developed. | 2014 | Washington, District Of Columbia, United States | USD 25.88 M | – | – | |
Offers Ayurvedic treatments, consultations, and products for various diseases and wellness. | 1992 | Faridabad, Haryana, India | – | USD 10.08 M | 570 | |
Ayurvedic company manufacturing natural soaps, body washes, and health products. | 1969 | Chennai, Tamil Nadu, India | – | USD 51.17 M | 418 | |
Chinese medicines are researched, developed, manufactured, and supplied. | 2001 | Heze, Shandong, China | – | USD 1.68 B | – | |
Herbal medicines and supplements for health categories are manufactured. | 1933 | Neumarkt-sankt Veit, Bavaria, Germany | – | USD 510.09 M | 196 | |
Provides Ayurvedic healing therapies, massages, and wellness services in India. | – | Kochi, Kerala, India | – | USD 230.35 K | 42 | |
Homeopathic medicines are supplied and distributed by Boiron worldwide. | 1932 | Newtown Square, Pennsylvania, United States | – | – | – | |
Ayurvedic personal and sexual wellness products are manufactured and distributed. | 2015 | Mumbai, Maharashtra, India | – | USD 15.13 M | 38 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Bijoy Hans Limited
Complete news archive for Bijoy Hans Limited
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Bijoy Hans Limited
Bijoy Hans Limited is headquartered in Guwahati, India. It is registered at Guwahati, Assam, India.
The primary company behind Bijoy Hans Limited, Arvaya Healthcare Limited, reported revenue of ₹46.9 Lakh for FY 2025, down 20% year on year.
Bijoy Hans Limited was incorporated in 1985 and is situated in Guwahati, where various pharmaceutical formulations such as tablets, capsules, syrups, suspensions, and powders are produced. A focus is placed on segments including Antibiotics, CoughColdAllergy remedies, H-1 Receptor Antagonists, Nutraceuticals, and NSAIDS. The companys objectives are centered on benefiting shareholders, meeting customer requirements, ensuring continuous product improvement, and delivering sustainable excellence in health, safety, security, and environmental practices. Compliance with regulations is maintained through regular financial reporting and investor relations activities.
Bijoy Hans Limited offers Pharmaceutical Formulations and Nutraceuticals.
Yes, Bijoy Hans Limited is publicly traded on BSE under the ticker symbol ARVAYA.
Bijoy Hans Limited operates through Arvaya Healthcare Limited.
The legal entities of Bijoy Hans Limited currently have 8 directors, including Kaushal Uttam Shah, Rahul Ravindra Mayur, Salil Sriram Shetty and others.